MedPath

ASP-3291

Generic Name
ASP-3291

Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis

Phase 2
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: Placebo
First Posted Date
2012-06-05
Last Posted Date
2016-09-28
Lead Sponsor
Telsar Pharma Inc.
Target Recruit Count
112
Registration Number
NCT01612039

A Study of a Single Dose of ASP3291 in Subjects With Ulcerative Colitis

Phase 1
Completed
Conditions
Ulcerative Colitis
Interventions
Drug: Placebo
First Posted Date
2011-03-22
Last Posted Date
2012-07-24
Lead Sponsor
Telsar Pharma Inc.
Target Recruit Count
16
Registration Number
NCT01320332
Locations
🇺🇸

Advanced Clinical Research Institute, Anaheim, California, United States

🇺🇸

Clinical Trials of Texas, Inc., San Antonio, Texas, United States

🇺🇸

SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath